135 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
company. AbbVie uses its expertise, dedicated people, and unique approach to innovation to develop and market advanced therapies that address some … , and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie’s
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex … to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie’s common stock is listed
DEFA14A
IMGN
Immunogen, Inc.
21 Dec 23
Additional proxy soliciting materials
3:54pm
expertise, dedicated people, and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex
DEFA14A
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:08pm
receive an invitation to a small gathering this afternoon at 4PM in the Innovation Zone. We’ll pop a few bottles and have a few snacks to celebrate today’s … in the Innovation Zone. In the meantime, please direct any specific questions you might have to your ExCo leader.
ALL COMPANY MEETING
ME Script
DEFA14A
EX-99.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
is an exciting opportunity for the combined companies to advance innovation in ADCs. This transaction is the culmination of our 40-year commitment
8-K
EX-99.1
d7leyww0dp5gg16
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
424B5
iewfy35v1ra1kj0
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
qw9v5jd7t
3 May 23
Prospectus supplement for primary offering
4:05pm